Loading
Life sciences · Journal article
Frontiers in Oncology · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Immune checkpoint inhibitors have improved outcomes in selected patients with breast cancer, particularly those with triple-negative disease, but most tumors remain refractory. Abnormal tumor vasculature is one contributor to this resistance. Disorganized, hyperpermeable vessels produce heterogeneous perfusion, hypoxia, acidosis, and elevated interstitial pressure; these changes impede drug delivery and lymphocyte trafficking while favoring regulatory T cells, myeloid-derived suppressor cells, and dysfunctional antigen presentation. Anti-angiogenic therapy can transiently reverse part of this phenotype. When dose and timing are appropriate, a vascular-normalization window improves perfusion and oxygenation, restores endothelial adhesiveness, and creates conditions in which chemotherapy and immune checkpoint blockade may work more effectively. This framework is biologically compelling, but clinical evidence in breast cancer remains uneven: activity has been reported in several early-phase combination studies, whereas large trials of bevacizumab-containing regimens have not consistently improved overall survival. Candidate biomarkers—including VEGF/VEGFR signaling, angiopoietin–Tie2 activity, PD-L1, high endothelial venules, tertiary lymphoid structures, circulating cytokines, and spatial patterns of immune exclusion—remain exploratory and are limited by assay variability and temporal heterogeneity. This narrative review examines the vascular – immune interface across breast cancer subtypes, distinguishes mechanistic rationale from clinical proof, and identifies priorities for biomarker-guided trials designed to define dose, sequence, and the normalization window.